

Acute Myeloid Leukemia Quality of Life Questionnaire (AML-QOL)

Business Opportunity

Exclusive license
Sponsored research
Sponsored research

Technology Type

Quality of Life
Questionnaire

State of Development

QoL fully developed and
validated

Patent Information

Copyright

Investigator

Stephanie Lee, MD, MPH
David and Patricia
Giuliani/Oliver Press
Endowed Chair in Cancer
Research
Fred Hutch

Tech ID

18-155

Contact

partnering@fredhutch.org

Brief Description

A validated and reliable quality of life instrument that is specific to patients with acute myeloid leukemia.

Technology Overview

Researchers at Fred Hutchinson Cancer center has developed a novel and validated quality of life instrument specifically designed for patients with acute myeloid leukemia (AML). Developed through an iterative process involving feedback from patients, medical providers, and psychometricians, the AML-QOL underwent rigorous testing and validation, including factor analysis and test-retest reliability studies with 202 patients. The final instrument includes 27 items organized into 5 domains, a Symptom Index, and a Summary Score. The AML-QOL has been shown to have high internal consistency, good test-retest reliability, and strong convergent and divergent validity when compared to a non-disease-specific instrument. Furthermore, the Summary Score demonstrates good sensitivity to change when anchored to patient perception of QOL change, providing a clinically meaningful difference of 8-10 points out of 100. The AML-QOL is a reliable and valid measure of quality of life for patients with AML and other aggressive myeloid neoplasms.

Applications

- Assessing quality of life of patients with AML and other cancers

Advantages

- Specifically designed for patients with acute myeloid leukemia (AML) and other aggressive myeloid neoplasms.
- Demonstrated high internal consistency, good test-retest reliability, and strong convergent and divergent validity.